PCIF1 and neoplasm: To investigate whether targeting PCIF1 could enhance the efficacy of anti‐PD1 immunotherapy in OSCC, we conducted a comparative analysis of tumour progression in PCIF1‐knockout mice treated with either anti‐PD1 antibody or IgG control (Figure 7A).